» Articles » PMID: 36790505

Intrathymic AAV Delivery Results in Therapeutic Site-specific Integration at TCR Loci in Mice

Abstract

Adeno-associated virus (AAV) vectors have been successfully exploited in gene therapy applications for the treatment of several genetic disorders. AAV is considered an episomal vector, but it has been shown to integrate within the host cell genome after the generation of double-strand DNA breaks or nicks. Although AAV integration raises some safety concerns, it can also provide therapeutic benefit; the direct intrathymic injection of an AAV harboring a therapeutic transgene results in integration in T-cell progenitors and long-term T-cell immunity. To assess the mechanisms of AAV integration, we retrieved and analyzed hundreds of AAV integration sites from lymph node-derived mature T cells and compared these with liver and brain tissue from treated mice. Notably, we found that although AAV integrations in the liver and brain were distributed across the entire mouse genome, >90% of the integrations in T cells were clustered within the T-cell receptor α, β, and γ genes. More precisely, the insertion mapped to DNA breaks created by the enzymatic activity of recombination activating genes (RAGs) during variable, diversity, and joining recombination. Our data indicate that RAG activity during T-cell receptor maturation induces a site-specific integration of AAV genomes and opens new therapeutic avenues for achieving long-term AAV-mediated gene transfer in dividing cells.

Citing Articles

Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors.

Singh K, Fronza R, Evens H, Chuah M, VandenDriessche T Mol Ther Methods Clin Dev. 2024; 32(4):101365.

PMID: 39655309 PMC: 11626537. DOI: 10.1016/j.omtm.2024.101365.


Modulation of AAV transduction and integration targeting by topoisomerase poisons.

Kasimsetty A, Hwang Y, Everett J, McFarland A, Zolnoski S, Lu T Mol Ther Methods Clin Dev. 2024; 32(4):101364.

PMID: 39618424 PMC: 11607603. DOI: 10.1016/j.omtm.2024.101364.


AAV-mediated genome editing is influenced by the formation of R-loops.

Puzzo F, Crossley M, Goswami A, Zhang F, Pekrun K, Garzon J Mol Ther. 2024; 32(12):4256-4271.

PMID: 39369271 PMC: 11638834. DOI: 10.1016/j.ymthe.2024.09.035.


AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription.

Bazick H, Mao H, Niehaus J, Wolter J, Zylka M Mol Ther. 2024; 32(11):4122-4137.

PMID: 39367606 PMC: 11573598. DOI: 10.1016/j.ymthe.2024.09.032.


T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8.

Demircan M, Zinser L, Michels A, Guaza-Lasheras M, John F, Gorol J Mol Ther. 2024; 32(10):3470-3484.

PMID: 39113357 PMC: 11489536. DOI: 10.1016/j.ymthe.2024.08.002.


References
1.
Nault J, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G . Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015; 47(10):1187-93. DOI: 10.1038/ng.3389. View

2.
Dudek A, Porteus M . Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Gene Editing. Front Immunol. 2021; 12:660302. PMC: 8195279. DOI: 10.3389/fimmu.2021.660302. View

3.
Kadlecek T, van Oers N, Lefrancois L, Olson S, Finlay D, Chu D . Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol. 1998; 161(9):4688-94. View

4.
Morabito G, Giannelli S, Ordazzo G, Bido S, Castoldi V, Indrigo M . AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. Mol Ther. 2017; 25(12):2727-2742. PMC: 5768559. DOI: 10.1016/j.ymthe.2017.08.004. View

5.
Luoni M, Giannelli S, Indrigo M, Niro A, Massimino L, Iannielli A . Whole brain delivery of an instability-prone transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome. Elife. 2020; 9. PMC: 7117907. DOI: 10.7554/eLife.52629. View